BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31216227)

  • 1. Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation.
    Correa AF; Jegede O; Haas NB; Flaherty KT; Pins MR; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Dutcher JP; DiPaola RS; Carducci MA; Uzzo RG
    J Clin Oncol; 2019 Aug; 37(23):2062-2071. PubMed ID: 31216227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival following cytoreductive nephrectomy: a comparison of existing prognostic models.
    Westerman ME; Shapiro DD; Tannir NM; Campbell MT; Matin SF; Karam JA; Wood CG
    BJU Int; 2020 Dec; 126(6):745-753. PubMed ID: 32623821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort.
    Klatte T; Gallagher KM; Afferi L; Volpe A; Kroeger N; Ribback S; McNeill A; Riddick ACP; Armitage JN; 'Aho TF; Eisen T; Fife K; Bex A; Pantuck AJ; Stewart GD
    BMC Med; 2019 Oct; 17(1):182. PubMed ID: 31578141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of recurrence after nephrectomy: Comparison of predictive ability of validated risk models.
    Palumbo C; Perri D; Zacchero M; Bondonno G; Martino JD; D'Agate D; Volpe A
    Urol Oncol; 2022 Apr; 40(4):167.e1-167.e7. PubMed ID: 35034803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A CT-based deep learning radiomics nomogram outperforms the existing prognostic models for outcome prediction in clear cell renal cell carcinoma: a multicenter study.
    Nie P; Yang G; Wang Y; Xu Y; Yan L; Zhang M; Zhao L; Wang N; Zhao X; Li X; Cheng N; Wang Y; Chen C; Wang N; Duan S; Wang X; Wang Z
    Eur Radiol; 2023 Dec; 33(12):8858-8868. PubMed ID: 37389608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data.
    Speed JM; Trinh QD; Choueiri TK; Sun M
    Curr Urol Rep; 2017 Feb; 18(2):15. PubMed ID: 28213859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 'Stage, Size, Grade and Necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma.
    Ficarra V; Novara G; Galfano A; Brunelli M; Cavalleri S; Martignoni G; Artibani W
    BJU Int; 2009 Jan; 103(2):165-70. PubMed ID: 18782313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study.
    Cindolo L; Patard JJ; Chiodini P; Schips L; Ficarra V; Tostain J; de La Taille A; Altieri V; Lobel B; Zigeuner RE; Artibani W; Guillé F; Abbou CC; Salzano L; Gallo C
    Cancer; 2005 Oct; 104(7):1362-71. PubMed ID: 16116599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.
    Buti S; Puligandla M; Bersanelli M; DiPaola RS; Manola J; Taguchi S; Haas NB
    Ann Oncol; 2017 Nov; 28(11):2747-2753. PubMed ID: 28945839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The radiomics-based tumor heterogeneity adds incremental value to the existing prognostic models for predicting outcome in localized clear cell renal cell carcinoma: a multicenter study.
    Yang G; Nie P; Yan L; Zhang M; Wang Y; Zhao L; Li M; Xie F; Xie H; Li X; Xiang F; Wang N; Cheng N; Zhao X; Wang N; Wang Y; Chen C; Yun C; Cui J; Duan S; Zhang R; Hao D; Wang X; Wang Z; Niu H
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2949-2959. PubMed ID: 35344062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting recurrence and survival in patients with non-metastatic renal-cell carcinoma after nephrectomy: a prospective population-based study with multicenter validation.
    Wang Y; Xuan Y; Su B; Gao Y; Fan Y; Huang Q; Zhang P; Gu L; Niu S; Shen D; Li X; Wang B; Zhu Q; Ouyang Z; Xie J; Ma X
    Int J Surg; 2024 Feb; 110(2):820-831. PubMed ID: 38016139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma.
    Correa AF; Jegede OA; Haas NB; Flaherty KT; Pins MR; Adeniran A; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Dutcher JP; DiPaola RS; Carducci MA; Uzzo RG
    Eur Urol; 2021 Jul; 80(1):20-31. PubMed ID: 33707112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805).
    Xu W; Puligandla M; Halbert B; Haas NB; Flaherty KT; Uzzo RG; Dutcher JP; DiPaola RS; Sabbisetti V; Bhatt RS
    Clin Cancer Res; 2021 Jun; 27(12):3397-3403. PubMed ID: 33832947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk models for recurrence and survival after kidney cancer: a systematic review.
    Usher-Smith JA; Li L; Roberts L; Harrison H; Rossi SH; Sharp SJ; Coupland C; Hippisley-Cox J; Griffin SJ; Klatte T; Stewart GD
    BJU Int; 2022 Nov; 130(5):562-579. PubMed ID: 34914159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated staging systems for conventional renal cell carcinoma: a comparison of two prognostic models.
    Martella O; Galatioto GP; Necozione S; Pomante R; Vicentini C
    Arch Ital Urol Androl; 2011 Sep; 83(3):121-7. PubMed ID: 22184835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the current prognostic models for nonmetastatic renal cell carcinoma after nephrectomy in Chinese population: a 15-year single center experience.
    Liu Z; Lv J; Ding K; Fu Q; Cao Q; Wang F
    Int J Urol; 2009 Mar; 16(3):268-73. PubMed ID: 19087209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
    Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
    Lam JS; Shvarts O; Said JW; Pantuck AJ; Seligson DB; Aldridge ME; Bui MH; Liu X; Horvath S; Figlin RA; Belldegrun AS
    Cancer; 2005 Jun; 103(12):2517-25. PubMed ID: 15880379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems.
    Lamb GW; Aitchison M; Ramsey S; Housley SL; McMillan DC
    Br J Cancer; 2012 Jan; 106(2):279-83. PubMed ID: 22166802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study.
    Patard JJ; Kim HL; Lam JS; Dorey FJ; Pantuck AJ; Zisman A; Ficarra V; Han KR; Cindolo L; De La Taille A; Tostain J; Artibani W; Dinney CP; Wood CG; Swanson DA; Abbou CC; Lobel B; Mulders PF; Chopin DK; Figlin RA; Belldegrun AS
    J Clin Oncol; 2004 Aug; 22(16):3316-22. PubMed ID: 15310775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.